Leuk Res. 2006 Mar;30 Suppl 1:S11-5.

Rituximab maintenance therapy in indolent NHL: a clinical review.

Source

Nedizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians-Universitat, Munich, Germany. buske@gsf.de

Abstract

Rituximab maintenance therapy following successful induction has emerged as a highly effective treatment for follicular lymphoma. Several randomized trials have been conducted analyzing the impact of rituximab maintenance compared to observation alone on treatment outcome. These studies have been conducted in patients receiving single-agent rituximab, standard chemotherapy or rituximab plus chemotherapy as initial cytoreduction, in both previously treated and untreated patients. In all the trials, rituximab maintenance resulted in a clinically and statistically significant benefit in clinical endpoints such as progression-free survival. Moreover, first data indicate that rituximab maintenance can prolong overall survival in patients with follicular lymphoma. These data have established rituximab maintanance as an important part of multimodal therapeutic strategies. Ongoing studies will help to determine the best schedule for the maintenance therapy in the treatment of follicular lymphoma.

PMID:: 16750673; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. [J Natl Cancer Inst. 2009]
Review Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O. J Natl Cancer Inst. 2009 Feb 18; 101(4):248-55. Epub 2009 Feb 10.
Review Rituximab as maintenance therapy for patients with follicular lymphoma. [Cochrane Database Syst Rev. 2009]
Review Rituximab as maintenance therapy for patients with follicular lymphoma.
Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Cochrane Database Syst Rev. 2009 Apr 15; (2):CD006552. Epub 2009 Apr 15.
Review Prolonging remission with rituximab maintenance therapy. [Semin Oncol. 2004]
Review Prolonging remission with rituximab maintenance therapy.
Hainsworth JD. Semin Oncol. 2004 Feb; 31(1 Suppl 2):17-21.
Review Use of rituximab in patients with follicular lymphoma. [Clin Oncol (R Coll Radiol). 2007]
Review Use of rituximab in patients with follicular lymphoma.
Marcus R. Clin Oncol (R Coll Radiol). 2007 Feb; 19(1):38-49.
Review What is the role of maintenance rituximab in follicular NHL? [Oncology (Williston Park). 2008]
Review What is the role of maintenance rituximab in follicular NHL?
Maloney DG. Oncology (Williston Park). 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4.

See reviews... See all...

Cited by 2 PubMed Central articles

Review Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. [Clin Dev Immunol. 2010]
Review Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.
Motta G, Cea M, Moran E, Carbone F, Augusti V, Patrone F, Nencioni A. Clin Dev Immunol. 2010; 2010:428253. Epub 2011 Mar 6.
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. [Haematologica. 2009]
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.
Ziakas PD, Karsaliakos P, Mylonakis E. Haematologica. 2009 Jul; 94(7):998-1005. Epub 2009 May 19.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Rituximab maintenance therapy in indolent NHL: a clinical review.
Rituximab maintenance therapy in indolent NHL: a clinical review.
Leuk Res. 2006 Mar ;30 Suppl 1:S11-5.

PubMed
MH2 domain of Smad3 reduces HIV-1 Tat-induction of cytokine secretion.
MH2 domain of Smad3 reduces HIV-1 Tat-induction of cytokine secretion.
J Neuroimmunol. 2006 Jul ;176(1-2):174-80. Epub 2006 Jun 5 .

PubMed
Immediate versus deferred androgen deprivation treatment in patients with node-p...
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Lancet Oncol. 2006 Jun ;7(6):472-9.

PubMed
Rest and postural tremors in patients with Parkinson's disease.
Rest and postural tremors in patients with Parkinson's disease.
Brain Res Bull. 2006 Jun 15 ;70(1):44-8. Epub 2005 Dec 15 .

PubMed
Apraclonidine and timolol. Combined effects in previously untreated normal subje...
Apraclonidine and timolol. Combined effects in previously untreated normal subjects.
Arch Ophthalmol. 1991 Jun ;109(6):804-6.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: